((自动化翻译由路透提供,请见免责声明 ))
路透法兰克福10月23日 - 瑞士制药巨头罗氏 的首席执行官说,竞争管理机构不应允许诺和诺德 的控股股东收购合同药品生产商康泰伦特 。
"这对我们来说不是问题,但对其他小企业来说可能是个问题,如果对(合同制造商)。罗氏公司首席执行官托马斯-希内克尔(Thomas Schinecker)在季度销售额公布后的媒体电话会议上说:"从行业角度看,这将是当局的一个错误决定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.